Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: The development of frailty at hospital discharge affects the clinical outcomes in severe coronavirus disease 2019 (COVID-19) survivors who had no frailty before hospitalization. We aimed to describe the prevalence of new frailty using the clinical frailty scale (CFS) and evaluate its associated factors in patients with severe COVID-19 without pre-existing frailty before hospitalization.

Methods: We performed a secondary analysis of clinical data from a nationwide retrospective cohort collected from 22 hospitals between January 1, 2020 and August 31, 2021. The patients were at least 19 years old and survived until discharge after admission to the intensive care unit (ICU) because of severe COVID-19. Development of new frailty was defined as a CFS score ≥5 at hospital discharge.

Results: Among 669 severe COVID-19 survivors without pre-existing frailty admitted to the ICU, the mean age was 65.2±12.8 years, 62.5% were male, and 50.2% received mechanical ventilation (MV). The mean CFS score at admission was 2.4±0.9, and new frailty developed in 27.8% (186/483). In multivariate analysis, older age, cardiovascular disease, CFS score of 3-4 before hospitalization, increased C-reactive protein level, longer duration of corticosteroid treatment, and use of MV and extracorporeal membrane oxygenation were identified as factors associated with new-onset frailty.

Conclusion: Our study suggests that new frailty is not uncommon and is associated with diverse factors in survivors of severe COVID-19 without pre-existing frailty.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010708PMC
http://dx.doi.org/10.4046/trd.2024.0160DOI Listing

Publication Analysis

Top Keywords

severe covid-19
20
covid-19 survivors
12
pre-existing frailty
12
cfs score
12
frailty
10
prevalence frailty
8
frailty hospital
8
hospital discharge
8
associated factors
8
development frailty
8

Similar Publications

Repurposing disulfiram: An innovative inhibitory approach against a broad spectrum of viruses.

Biochem Biophys Res Commun

September 2025

Department of Clinical Laboratory Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China; Department of Pathogen Biology, School of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandon

Disulfiram (DSF), an FDA-approved therapeutic agent for alcohol dependence, has recently attracted considerable interest due to its broad-spectrum inhibitory effects against various viruses. Increasing evidence suggests that DSF can inhibit viral replication through two major mechanisms: the inhibition of viral protein catalytic activity and the ejection of Zn from viral proteins. This review comprehensively summarized the molecular mechanisms underlying DSF's antiviral activity against viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), hepatitis C virus (HCV), influenza virus, human immunodeficiency virus (HIV), and Kaposi sarcoma-associated herpes virus (KSHV), with a particular focus on its dual targeting of Cys residues and Zn coordination sites.

View Article and Find Full Text PDF

C-reactive protein levels at admission among stroke patients - A comparative analysis.

Clin Neurol Neurosurg

September 2025

Neurovascular Research Unit, Department of Neurology, Copenhagen, University Hospital - Herlev and Gentofte, Herlev, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Department of Brain, and Spinal Cord Injury, Copenhagen University Hospital - Rigshospitalet,

Objective: Severity and outcome of stroke may be associated with a concomitant or subsequent inflammatory response. C-reactive protein (CRP) may correlate with length of stay (LOS) in hospital, indicating increased complexity of stroke patients with an ongoing inflammatory reaction upon admission.

Methods: This retrospective cross-sectional study used data from admissions to the non-comprehensive Stroke Unit, which receives patients ineligible for revascularization therapy at Herlev-Gentofte hospital, in 2019 and 2020.

View Article and Find Full Text PDF

Wastewater surveillance of SARS-CoV-2 and influenza in a dynamic university community: understanding how wastewater measurements correspond to reported cases.

Sci Total Environ

September 2025

Department of Biology, The Pennsylvania State University, University Park, PA 16802, USA; Huck Institutes of the Life Sciences, The Pennsylvania State University, University Park, PA 16801, USA. Electronic address:

Wastewater surveillance is increasingly an effective public health tool for responding to epidemics and preparing for annual cycles of respiratory illnesses. We measured genetic markers from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), influenza A virus (IAV) and influenza B virus (IBV) in untreated wastewater of a university campus and its local residential community over a four-year period using digital Polymerase Chain Reaction (PCR) methods. These data were then analyzed and compared to clinical case data reported to the state by zip code.

View Article and Find Full Text PDF

Impact of the COVID-19 pandemic on melanoma: A retrospective study from the French clinical database of melanoma patients (RIC-Mel).

Ann Dermatol Venereol

September 2025

Université Grenoble Alpes, Service de dermatologie, Centre Hospitalier Universitaire, Grenoble, France; UGA/Inserm U 1209/CNRS UMR 5309 Joint Research Center, Institute for Advanced Biosciences, 38700 La Tronche, France.

Background: COVID-19 pandemic had a variable impact on the severity of melanomas.

Objective: To assess the role of the COVID-19 pandemic in France on the severity of melanomas at initial diagnosis.

Methods: New melanoma cases recorded in the French RIC-Mel database were included in a retrospective study spanning three timeframes: pre-COVID (01/01/2018 to 03/16/2020), lockdown (03/17/2020 to 10/05/2020), and the COVID pandemic period (hereafter referred to as "COVID") (11/05/2020 to 30/09/2022).

View Article and Find Full Text PDF